Akila Balachandran

Akila is curious about identification of novel targeted therapies for cancer. Her PhD emphasises development of novel splice-modulating antisense oligonucleotides as potential therapeutics for liver and other solid cancers. She would also focus on generating aptamers that could aid in early diagnosis of neurological disorders. Aptamers are single stranded oligonucleotides that can fold into unique three dimensional structure thereby facilitating target specific binding.